CA15-3

Aliases
  • ADMCKD
  • ADMCKD1
  • Breast Carcinoma-Associated Antigen DF3
  • CA 15-3
  • CA15-3
  • CA15.3
  • CD227
  • CD227 Antigen
  • Cancer Antigen 15-3
  • Carcinoma-Associated Mucin
  • DF3 Antigen
  • EMA
  • Episialin
  • H23 Antigen
  • H23AG
  • KL-6
  • Krebs Von Den Lungen-6
  • MAM6
  • MCD
  • MCKD
  • MCKD1
  • MUC-1
  • MUC-1/SEC
  • MUC-1/X
  • MUC1
  • MUC1/ZD
  • Medullary Cystic Kidney Disease 1 (Autosomal Dominant)
  • Medullary Cystic Kidney Disease, Autosomal Dominant
  • Mucin 1, Cell Surface Associated
  • Mucin 1, Transmembrane
  • Mucin-1
  • PEM
  • PEMT
  • PUM
  • Peanut-Reactive Urinary Mucin
  • Polymorphic Epithelial Mucin
  • Tumor Associated Epithelial Mucin
  • Tumor-Associated Epithelial Membrane Antigen
  • Tumor-Associated Mucin
Description
From NCBI Gene: This gene encodes a membrane-bound protein that is a member of the mucin family. Mucins are O-glycosylated proteins that play an essential role in forming protective mucous barriers on epithelial surfaces. These proteins also play a role in intracellular signaling. This protein is expressed on the apical surface of epithelial cells that line the mucosal surfaces of many different tissues including lung, breast stomach and pancreas. This protein is proteolytically cleaved into alpha and beta subunits that form a heterodimeric complex. The N-terminal alpha subunit functions in cell-adhesion and the C-terminal beta subunit is involved in cell signaling. Overexpression, aberrant intracellular localization, and changes in glycosylation of this protein have been associated with carcinomas. This gene is known to contain a highly polymorphic variable number tandem repeats (VNTR) domain. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Feb 2011]
OncoMX

Search for this biomarker in OncoMX  

Attributes
QA State
Accepted
Type
Protein
HGNC Name
MUC1
Certifications
  • None
QA State for Breast
Curated

 Non-Public Biomarker

Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.

Certifications
  • None
QA State for Lung
Under Review

 Non-Public Biomarker

Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.

Certifications
  • None
QA State for Ovary
Accepted
Organ-Specific Notes

CA15-3 may be a molecular marker for ovarian cancer. Literature suggests that the concomitant measurement of CA15-3 with CA125 could be advantageous in the pre-operative discrimination of benign and malignant ovarian tumors.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. CA15-3 alone was not a strong predictor.

Supporting Study Data
PLCO Ovarian Phase III Validation Study
Study phase on the ovary: 3

Our preliminary data indicate that the performance of CA 125 as a screening test for ovarian cancer can be improved upon by additional biomarkers. With completion of one additional validation step, we will be ready to test the performance of a consensus marker panel in a phase III validation study. Given the original aims of the PLCO trial, we believe that the PLCO represents an ideal longitudinal cohort offering specimens for phase III validation of ovarian cancer biomarkers.

View Protocol
Decision rule: PMID:21372037
SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study
Study phase on the ovary: 3

Create a new set of phase II specimens (160 cases with pre-operative bloods representing major histologic types and including 80 early-staged and 80 late-staged cases, 160 controls with benign disease, 480 general population controls, and a small set of serial Samples collected either at least 3 months apart, but not more than 6 months apart OR between 10 months apart and no more than 14 months apart in 40 healthy controls) will be used to evaluate markers identified in preliminary work. The top 5-10 markers, plus an expanded panel of Luminex markers, will comprise a “working consensus panel” for subsequent analysis in PLCO specimens.

View Protocol
Decision rule: PMID:21372037
Ovary-Specific Protocols
  • No organ-level protocols specified for ovary.
Ovary-Specific Publications
  • No organ-level publications were listed for ovary.
Ovary-Specific Resources
  • No organ-level resources were given for ovary.
Certifications
  • None
QA State for Prostate
Under Review

 Non-Public Biomarker

Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.